Data

Resolving tissue-level proteomic complexity in cutaneous squamous cell carcinoma (cSCC) with ultra high-plex spatial profiling

The University of Queensland
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.48610/7078364&rft.title=Resolving tissue-level proteomic complexity in cutaneous squamous cell carcinoma (cSCC) with ultra high-plex spatial profiling&rft.identifier=RDM ID: 1ee32ae6-a38f-4e27-8a2a-0312ec944af7&rft.publisher=The University of Queensland&rft.description=Cutaneous squamous cell carcinoma (cSCC) represents a major global health burden. Immune-checkpoint inhibitors (ICIs) are the primary treatment for advanced cSCC with durable responses. However, resistance to ICI is associated with a poor prognosis. More translational methods to profile the tumour microenvironment (TME) are needed. In this study, we demonstrate proof-of-concept for high-plex spatial proteomics 1116 proteins (GeoMx Discovery Protein Atlas, Bruker Spatial Biology) to profile 190 pathology-reviewed, consecutively gridded, tissue-compartments across the tumour and stromal regions revealing expression profiles underscored by metabolic and immunological activity. These signatures differentiate immunocompetent and immunocompromised cSCC patients by varying immune competency, including type I interferon signalling. Taken together, this study demonstrates utility for discovery spatial proteomics in a translationally focussed setting for cSCC.&rft.creator=Anonymous&rft.date=2025&rft_rights= https://guides.library.uq.edu.au/deposit-your-data/license-reuse-data-agreement&rft_subject=eng&rft_subject=Cancer genetics&rft_subject=Oncology and carcinogenesis&rft_subject=BIOMEDICAL AND CLINICAL SCIENCES&rft.type=dataset&rft.language=English Access the data

Contact Information

[email protected]
Frazer Institute

Full description

Cutaneous squamous cell carcinoma (cSCC) represents a major global health burden. Immune-checkpoint inhibitors (ICIs) are the primary treatment for advanced cSCC with durable responses. However, resistance to ICI is associated with a poor prognosis. More translational methods to profile the tumour microenvironment (TME) are needed. In this study, we demonstrate proof-of-concept for high-plex spatial proteomics 1116 proteins (GeoMx Discovery Protein Atlas, Bruker Spatial Biology) to profile 190 pathology-reviewed, consecutively gridded, tissue-compartments across the tumour and stromal regions revealing expression profiles underscored by metabolic and immunological activity. These signatures differentiate immunocompetent and immunocompromised cSCC patients by varying immune competency, including type I interferon signalling. Taken together, this study demonstrates utility for discovery spatial proteomics in a translationally focussed setting for cSCC.

Issued: 2025

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers